Compare GCTS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | IPHA |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | France |
| Employees | 126 | 163 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.4M | 189.5M |
| IPO Year | N/A | N/A |
| Metric | GCTS | IPHA |
|---|---|---|
| Price | $2.47 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.50 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 3.3M | 9.0K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,052.30 | $180.36 |
| Revenue Next Year | $140.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $1.18 |
| 52 Week High | $3.93 | $2.63 |
| Indicator | GCTS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 49.12 |
| Support Level | $2.35 | $1.70 |
| Resistance Level | $3.21 | $1.80 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 17.96 | 16.63 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.